drugset / Trial / NCT01794182

Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals

NCT01794182

Phase 2 Completed 86 enrolled Remedy Pharmaceuticals, Inc.
RandomizedParallel-groupQuadruple-blindPrevention

Summary

This is a randomized, multi-center, prospective, double blind study. The primary objective is to assess the efficacy and safety of glyburide (RP-1127) compared to placebo in participants with a severe anterior circulation ischemic stroke who are likely to develop malignant edema.This objective will be addressed by comparing the proportion of glyburide treated particpants and placebo treated participants with a Day 90 modified Rankin Scale (mRS) ≤ 4 without decompressive craniectomy (DC). The secondary objective is to assess the efficacy of RP-1127 compared to placebo in participants with a severe anterior circulation ischemic stroke who were likely to develop malignant edema.

Timeline

Start
2013-06-13
Primary completion
2016-04-04
Completion
2016-04-04

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Glyburide Small molecule 0.11 mg Intravenous

Indications